Clinical Trial Update: A Study of the Safety and Tolerability of MEDI-551 in Scleroderma [Phase 1]

View source ↗

Summary

This document summarizes the results of a Phase 1 study evaluating the safety and tolerability of MEDI-551 (inebilizumab) in patients with systemic sclerosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Sclerosis

Drugs mentioned

• MEDI-551 (inebilizumab)

Snippet

Sponsor: MedImmune LLC | Conditions: Scleroderma | Phase 1 | Status: COMPLETED